Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
IGEA PHARMA N.V. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.0005 CHF | -66.67% | -.--% | -98.44% | |
| Nov. 06 | Swiss Market Index Flat Amid Expected Labor Market Growth | MT |
| Nov. 06 | Appeals Board Upholds Decision to Delist IGEA Pharma from SIX Swiss Exchange on Questionable Solvency | MT |
| Sales 2022 * | - | Sales 2023 * | - | Capitalization | 10.89M 9.52M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -9.62M | Net income 2023 * | - | EV / Sales 2022 | - |
| Net Debt 2022 | 1.55M 1.35M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | -0,93x | P/E ratio 2023 * | Employees | 1 | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 65.88% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -66.67% | ||
| 1 month | -66.67% | ||
| 3 months | -66.67% | ||
| 6 months | -90.00% | ||
| Current year | -98.44% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.05
1 year
0.000.05
3 years
0.000.70
5 years
0.003.75
10 years
0.003.75
| Managers | Title | Age | Since |
|---|---|---|---|
Vicenzo Moccia
CEO | Chief Executive Officer | 63 | 2018 |
Rosanna Squitti
CTO | Chief Tech/Sci/R&D Officer | - | 2018 |
Anna Babuder
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Federico Bazzoni
BRD | Director/Board Member | 63 | 2018 |
Flavio Peralda
BRD | Director/Board Member | 72 | 2018 |
Rosanna Squitti
CTO | Chief Tech/Sci/R&D Officer | - | 2018 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 0.0005 | -.--% | 0 |
| 23-12-04 | 0.0005 | -.--% | 0 |
| 23-12-01 | 0.0005 | -.--% | 0 |
| 23-11-30 | 0.0005 | -.--% | 0 |
| 23-11-29 | 0.0005 | -.--% | 0 |
Delayed Quote Swiss Exchange, November 15, 2023 at 11:35 am EST
More quotes
IGEA Pharma NV is a biopharmaceutical company based in the Netherlands. The Company focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The Company develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer's disease. The Company offers its services in the Netherlands.
Calendar
2024-07-11
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
D
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -98.44% | 192 534 $ | |
| +0.69% | 12 584 M $ | |
| +24.40% | 5 358 M $ | |
| +42.60% | 4 977 M $ | |
| -32.91% | 5 023 M $ | |
| -14.10% | 4 321 M $ | |
| +1.50% | 2 439 M $ | |
| +123.05% | 1 849 M $ | |
| -3.51% | 1 903 M $ | |
| +21.56% | 1 634 M $ |
